Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 70% of Wholesalers Have Received Returns of “Opened and Resealed” Drugs: MHLW Survey
October 22, 2018
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme
October 19, 2018
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications
October 19, 2018
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan
October 19, 2018
- Council OKs Public Knowledge-Based Applications for Add’l Pediatric Indications for Blopress
October 19, 2018
- Chuikyo Wary on CEA Use for Reimbursement Decisions as MHLW Sorts Out Discussion Points towards Full Rollout
October 18, 2018
- 3 Pharma Groups Warn against Drug Price Cut in April 2019: Chuikyo
October 18, 2018
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients
October 17, 2018
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW
October 17, 2018
- As Abe Vows to Deliver on Tax Hike Plan, 3 Pharma Groups to Push for October 2019 Price Revision
October 16, 2018
- MEXT Kicks Off “Open Innovation Organization” Initiative, 3 Universities to Push Drug Discovery
October 15, 2018
- Nobel Laurate Honjo Prods Minister on Industry Consolidation
October 12, 2018
- MHLW Panelists Frown on Use of Economic Evaluations for Reimbursement Decisions
October 11, 2018
- MOF Reiterates Drug Cost Optimization, but Makes No Fresh Proposal: Fiscal System Council
October 10, 2018
- Govt Panel Kicks Off Discussions on “Social Security for All Generations”
October 9, 2018
- Social Security Cost Rise in FY2019 Should Be Held Under 500 Billion Yen: CEFP Members
October 9, 2018
- Reimbursement Policies for CAR-T, Other Pricey Drugs Might Come Up for Discussion on Oct. 10
October 5, 2018
- New Health Minister Stresses Needs for “Reasonable Drug Pricing”
October 4, 2018
- PM Abe Keen on Intensive 3-Year Reform for “All-Generation” Social Security, Taps Motegi to Lead Initiative
October 3, 2018
- Industry Rep Vows to Abide by Drug Detailing Guidelines
October 2, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…